Targeting Tumor-Intrinsic Hexosamine Biosynthesis Sensitizes Pancreatic Cancer to Anti-Pd1 Therapy

Journal of Clinical Investigation - United States
doi 10.1172/jci127515
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

American Society for Clinical Investigation

Related search

Targeting PIM Kinase With PD1 Inhibition Improves Immunotherapeutic Anti-Tumor T Cell Response

Clinical Cancer Research
Cancer ResearchOncology
2019English

Tumoral EHF Predicts the Efficacy of Anti-Pd1 Therapy in Pancreatic Ductal Adenocarcinoma

Journal of Experimental Medicine
MedicineAllergyImmunology
2019English

Response to Anti-Pd1 Therapy With Nivolumab in Metastatic Sarcomas

Clinical Sarcoma Research
Oncology
2016English

Targeting HSF1 Sensitizes Cancer Cells to HSP90 Inhibition

Oncotarget
Oncology
2013English

Endothelial-Cell FAK Targeting Sensitizes Tumours to DNA-damaging Therapy

Nature
Multidisciplinary
2014English

663. Targeting Tumor-Associated Macrophages for Cancer Therapy

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

Cancer Stroma-Targeting Therapy: A New Tool for Fighting Pancreatic Cancer?

Annals of Gastroenterological Surgery
2019English

Targeting PVR (CD155) and Its Receptors in Anti-Tumor Therapy

Cellular and Molecular Immunology
Infectious DiseasesMedicineAllergyImmunology
2018English

The Next Wave of Stroma-Targeting Therapy in Pancreatic Cancer

Cancer Research
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy